The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis. [electronic resource]
Producer: 20201124Description: 7921-7933 p. digitalISSN:- 1551-0018
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride -- adverse effects
- Exanthema -- chemically induced
- Humans
- Lung Neoplasms -- drug therapy
- Mutation
- Neutropenia -- chemically induced
- Odds Ratio
- Patient Safety
- Progression-Free Survival
- Protein Kinase Inhibitors -- adverse effects
No physical items for this record
Publication Type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.